Literature DB >> 17676372

Prognostic value of B-type natriuretic peptide in surgical palliation of children with single-ventricle congenital heart disease.

J G Berry1, B Askovich, R E Shaddy, J A Hawkins, C G Cowley.   

Abstract

The objective of this prospective study was to assess the prognostic role of perioperative B-type natriuretic peptide (BNP) levels in infants and children with single-ventricle congenital heart disease undergoing Norwood, bidirectional cavopulmonary anastomosis (BCPA), or Fontan operation. BNP levels were measured at baseline, after cardiopulmonary bypass, 6 to 12 hours after surgery, and then daily until indwelling vascular catheters were removed. Outcome measures included length of mechanical ventilation, inotropic support, and hospital stay. Twenty subjects underwent 23 surgical procedures (13 Norwood, 5 BCPA, and 5 Fontan). BNP levels were significantly higher in patients undergoing a Norwood procedure compared with a BCPA or Fontan procedure (p < 0.01). BNP levels measured 6 to 12 hours after surgery were predictive of duration of hospitalization (p = 0.005) and inotropic support (p = 0.01). An increase in BNP level within 48 hours of extubation was observed in 92% of patients undergoing a Norwood procedure. Early postoperative BNP levels correlate significantly with the ensuing duration of inotropic support and length of hospitalization. An increase in BNP after extubation may be reflective of the degree of underlying cardiopulmonary instability. Further investigation is necessary to define this important relation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17676372     DOI: 10.1007/s00246-007-9012-3

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  25 in total

1.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

Authors:  Charlotte Kragelund; Bjørn Grønning; Lars Køber; Per Hildebrandt; Rolf Steffensen
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

2.  Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.

Authors:  Sandeep R Das; Mark H Drazner; Daniel L Dries; Gloria L Vega; Harold G Stanek; Shuaib M Abdullah; Russell M Canham; Anne K Chung; David Leonard; Frank H Wians; James A de Lemos
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

Review 3.  Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease.

Authors:  B C Stein; R I Levin
Journal:  Am Heart J       Date:  1998-05       Impact factor: 4.749

4.  Ventricular expression of brain natriuretic peptide gene following orthotopic cardiac transplantation in children--a three year follow up.

Authors:  A Ationu; K Sorensen; B Whitehead; D Singer; M Burch; N D Carter
Journal:  Cardiovasc Res       Date:  1993-12       Impact factor: 10.787

Review 5.  Natriuretic peptides in assessment of left-ventricular dysfunction.

Authors:  J Mair; W Friedl; S Thomas; B Puschendorf
Journal:  Scand J Clin Lab Invest Suppl       Date:  1999

6.  Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease.

Authors:  Y Yamada; J Goto; M Yokota
Journal:  Cardiology       Date:  1997 Sep-Oct       Impact factor: 1.869

7.  Utility of B-type natriuretic peptide in predicting the level of peri- and postoperative cardiovascular support required after coronary artery bypass grafting.

Authors:  Brian H Cuthbertson; Alasdair McKeown; Bernard L Croal; William J Mutch; Graham S Hillis
Journal:  Crit Care Med       Date:  2005-02       Impact factor: 7.598

8.  Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery.

Authors:  Ryan Hutfless; Radmila Kazanegra; Michael Madani; Meenakshi Awasthi Bhalla; Alisi Tulua-Tata; Amelia Chen; Paul Clopton; Cherimarie James; Albert Chiu; Alan S Maisel
Journal:  J Am Coll Cardiol       Date:  2004-05-19       Impact factor: 24.094

9.  B-type natriuretic peptide levels in congenital heart disease.

Authors:  C G Cowley; J D Bradley; R E Shaddy
Journal:  Pediatr Cardiol       Date:  2004 Jul-Aug       Impact factor: 1.655

10.  Studies of cardiopulmonary bypass in children: implications for the regulation of brain natriuretic peptide.

Authors:  A Ationu; D R Singer; A Smith; M Elliott; M Burch; N D Carter
Journal:  Cardiovasc Res       Date:  1993-08       Impact factor: 10.787

View more
  5 in total

Review 1.  Plasma B-type natriuretic peptides in children with cardiovascular diseases.

Authors:  Bibhuti B Das
Journal:  Pediatr Cardiol       Date:  2010-10-07       Impact factor: 1.655

2.  Serum brain natriuretic peptide in children with Kawasaki disease.

Authors:  Yu-Ping Sun; Chao-Ping Wei; Wen-di Wang; Xing-Chang Zheng; Ye-Jun Wang; Shao-Chun Ma; Ying-Jun Xu
Journal:  World J Emerg Med       Date:  2010

Review 3.  NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies.

Authors:  Amiram Nir; Angelika Lindinger; Manfred Rauh; Benjamin Bar-Oz; Stephanie Laer; Lynn Schwachtgen; Andreas Koch; Jan Falkenberg; Thomas S Mir
Journal:  Pediatr Cardiol       Date:  2008-07-04       Impact factor: 1.655

Review 4.  The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.

Authors:  Massimiliano Cantinotti; Yuk Law; Simona Vittorini; Maura Crocetti; Marotta Marco; Bruno Murzi; Aldo Clerico
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

5.  Aminoterminal brain natriuretic peptide levels in children and adolescents after Fontan operation correlate with congestive heart failure.

Authors:  Evelyn Lechner; Roland Gitter; Rudolf Mair; Miklos Pinter; Elisabeth Schreier-Lechner; David Vondrys; Gerald Tulzer
Journal:  Pediatr Cardiol       Date:  2008-04-08       Impact factor: 1.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.